Consistent with animal experiments, hepatic fibrosis markers (<i>α</i>-SMA, collagen I, and CTGF) and inflammatory markers (IL-1<i>β</i>, IL-6, and TNF-<i>α</i>) were significantly decreased in activated LX-2 cells after PFD and/or AGP treatment. The gene discussed is SMN1; the disease is polyostotic fibrous dysplasia.